Recommendation of the President – Ramizek Plus (ramipril + bisoprolol fumarate)

On 23 April 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 58/2026 on the inclusion of the medicinal product Ramizek Plus (ramipril + bisoprolol fumarate) in the reimbursement scheme for the indication of substitution therapy for chronic coronary syndrome (following myocardial infarction or revascularization) or chronic heart failure with reduced left ventricular systolic function in adult patients adequately controlled with ramipril and bisoprolol administered simultaneously at the same dose as in the combination, but in the form of separate tablets

Publication in Public Information Bulletin (BIP) >>